http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021024191-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_193b3ba9731725f5faa4c6c60a876424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5513 |
| filingDate | 2020-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cdec9b12834024a8debdab09ad8a8b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_855fdb27a834d34ceb24cab92f63a278 |
| publicationDate | 2021-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021024191-A2 |
| titleOfInvention | Combination treatments with benzodiazepinone compounds and phosphoinositide 3-kinase pathway inhibitors for treating cancer |
| abstract | The present invention provides methods for treating a proliferative disorder in a subject comprising administering to the subject a first composition comprising one or more gamma secretase inhibitors and a second composition comprising one or more phosphoinositide 3-kinase (PI3K) pathway antagonists/inhibitors. This invention also provides methods for treating T-cell acute lymphoblastic leukemia (T-ALL) in a subject in need thereof comprising identifying elevated expression of T-ALL-specific transcription factors and administering to the subject a gamma secretase inhibitor and, optionally, a (PI3K) pathway antagonist/inhibitor, a transcription factor inhibitor, or a combination thereof. |
| priorityDate | 2019-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 909.